With Shire losing a case against Zydus, Mylan’s launches of generics Copaxone, Estrace and Sustiva and Teva following suit with its generic products for Estrace, Viagra and Minastrin 24 Fe - analysts (1) keep giving positive forecasts for the industry post-2018.
Will 2018-19 be a year of growth for generics Pharma?